The estimated Net Worth of William Wilson Troutman is at least $110 Tisíc dollars as of 20 August 2021. William Troutman owns over 5,000 units of Eton Pharmaceuticals stock worth over $110,299 and over the last 6 years William sold ETON stock worth over $0.
Sign up
William Troutman ETON stock SEC Form 4 insiders trading
William has made over 2 trades of the Eton Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently William bought 5,000 units of ETON stock worth $22,150 on 20 August 2021.
The largest trade William's ever made was buying 5,000 units of Eton Pharmaceuticals stock on 20 August 2021 worth over $22,150. On average, William trades about 1,667 units every 168 days since 2018. As of 20 August 2021 William still owns at least 23,027 units of Eton Pharmaceuticals stock.
You can see the complete history of William Troutman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's William Troutman's mailing address?
William's mailing address filed with the SEC is 21925 W FIELD PKWY, SUITE 235, , DEER PARK, IL, 60010-7278.
Insiders trading at Eton Pharmaceuticals
Over the last 6 years, insiders at Eton Pharmaceuticals have traded over $20,773,599 worth of Eton Pharmaceuticals stock and bought 488,500 units worth $3,287,585 . The most active insiders traders include Management Inc. Opaleye, Mark L Baum a Health, Inc. Harrow. On average, Eton Pharmaceuticals executives and independent directors trade stock every 61 days with the average trade being worth of $746,905. The most recent stock trade was executed by Sean Brynjelsen on 22 September 2022, trading 10,000 units of ETON stock currently worth $21,000.
What does Eton Pharmaceuticals do?
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
What does Eton Pharmaceuticals's logo look like?
Complete history of William Troutman stock trades at Eton Pharmaceuticals
Eton Pharmaceuticals executives and stock owners
Eton Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Sean Brynjelsen,
President, Chief Executive Officer, Director -
W. Troutman,
Chief Financial Officer, Treasurer, Secretary -
Sean E. Brynjelsen,
Pres, CEO & Director -
W. Wilson Troutman CPA,
CFO, Treasurer & Sec. -
Norbert Riedel,
Independent Chairman of the Board -
Paul Maier,
Independent Director -
Charles Casamento,
Independent Director -
Mark Baum,
Director -
Ingrid Hoos,
Senior Vice President - Scientific Affairs -
Kevin Guthrie,
Exec. VP of Commercial Operations -
James R. Gruber CPA,
CFO, Treasurer & Sec. -
David Krempa,
VP of Bus. Devel. -
Scott Grossenbach,
VP of Sales & Marketing -
Bharathi Devarakonda,
Sr. VP of Regulatory Affairs & Product Devel. -
Paul Stickler,
Sr. VP of Sales & Marketing -
Health, Inc. Harrow,
10% owner -
James R. Gruber,
Chief Financial Officer -
Management Inc. Opaleye,
10% owner -
Jennifer Mc Kie Adams,
Director -
David Krempa,
Chief Business Officer